Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out.

Cencora will sell its subsidiary MWI Animal Health to privately held Covetrus in a deal valuing the unit at $3.5 billion, the ...